140 related articles for article (PubMed ID: 31325170)
1. Validated HPLC method for simultaneous quantification of mutant IDH1/2 inhibitors (enasidenib, ivosidenib and vorasidenib) in mouse plasma: Application to a pharmacokinetic study.
Zakkula A; Dittakavi S; Maniyar MM; Syed N; Sulochana SP; Zainuddin M; Mullangi R
Biomed Chromatogr; 2019 Nov; 33(11):e4658. PubMed ID: 31325170
[TBL] [Abstract][Full Text] [Related]
2. Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study.
Dittakavi S; Hallur G; Purra BR; Kiran V; Zakkula A; Mullangi R
Drug Res (Stuttg); 2020 Jan; 70(1):41-48. PubMed ID: 31652462
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic Study.
Dittakavi S; Jat RK; Mullangi R
Drug Res (Stuttg); 2019 Sep; 69(9):505-511. PubMed ID: 30822797
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increased-sensitivity LC-MS/MS method: Application to a pharmacokinetic study.
Dittakavi S; Jat RK; Mullangi R
Biomed Chromatogr; 2019 Jun; 33(6):e4491. PubMed ID: 30663096
[TBL] [Abstract][Full Text] [Related]
5. Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Siddesh A; Sriram D; Zakkula A; Kumar R; Dittakavi S; Zainuddin M; Trivedi RK; Mullangi R
Biomed Chromatogr; 2021 Apr; 35(4):e5015. PubMed ID: 33125719
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study.
Zakkula A; Pulipati S; Dittakavi S; Bestha RM; Zainuddin M; Trivedi RK; Mullangi R
Drug Res (Stuttg); 2020 May; 70(5):233-238. PubMed ID: 32289835
[TBL] [Abstract][Full Text] [Related]
8. Validated HPLC Method for Quantification of a Novel Trk Inhibitor, Larotrectinib in Mice Plasma: Application to a Pharmacokinetic Study.
Tripathy HK; Nair Manju SV; Zakkula A; Bestha RM; Dittakavi S; Mullangi R
Drug Res (Stuttg); 2020 Feb; 70(2-03):101-106. PubMed ID: 31931548
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M
Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065
[TBL] [Abstract][Full Text] [Related]
10. RP-HPLC-UV Method for Simultaneous Quantification of Second Generation Non-Steroidal Antiandrogens Along with their Active Metabolites in Mice Plasma: Application to a Pharmacokinetic Study.
Zakkula A; Kiran V; Todmal U; Sulochana SP; Mullangi R
Drug Res (Stuttg); 2019 Oct; 69(10):537-544. PubMed ID: 30536259
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
12. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
Jiang X; Wada R; Poland B; Kleijn HJ; Fan B; Liu G; Liu H; Kapsalis S; Yang H; Le K
Clin Transl Sci; 2021 May; 14(3):942-953. PubMed ID: 33493392
[TBL] [Abstract][Full Text] [Related]
14. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, absorption, metabolism, and excretion of [
Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
[TBL] [Abstract][Full Text] [Related]
16. Validated HPLC-UV method for quantification of paxalisib, a pan PI3K and mTOR inhibitor in mouse plasma: Application to a pharmacokinetic study in mice.
Zakkula A; Tripathy HK; Bestha RM; Vinod AB; Kiran V; Dittakavi S; Mullangi R
Biomed Chromatogr; 2023 Apr; 37(4):e5587. PubMed ID: 36680551
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS/MS.
Xie S; Ye L; Ye X; Lin G; Xu RA
J Pharm Biomed Anal; 2020 Aug; 187():113353. PubMed ID: 32417565
[TBL] [Abstract][Full Text] [Related]
18. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
19. Determination and pharmacokinetic study of Enasidenib in rat plasma by UPLC-MS/MS.
Pang NH; Liu Q; Lu XR; Yang SF; Lin DD; Hu GX
J Pharm Biomed Anal; 2018 Aug; 157():165-170. PubMed ID: 29803908
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H
Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
